Full-Time

Environmental, Health & Safety Manager

CSL

CSL

10,001+ employees

Develops and delivers biotherapies and vaccines

No salary listed

Remote in Germany + 1 more

More locations: Marburg, Germany

Hybrid

The role covers the European CSL Plasma network; remote work is tied to Germany.

Bachelor's

Category
Facilities Operations (1)

Get referred to CSL

See people who can refer or advise you

Requirements
  • Typically a bachelor's degree in safety engineering, engineering, health management, occupational science, or a comparable field.
  • Qualification as an occupational safety specialist under the German Occupational Safety and Health Act (ASIG).
  • Current knowledge of German and European environmental, health, and safety legislation and employers' liability insurance association regulations.
  • At least 5 years of experience in a comparable work environment.
  • Good to very good English language skills.
Responsibilities
  • Support implementation of CSL Plasma's global and regional environmental, health, and safety strategies and programs and ensure alignment with overarching CSL EH&S goals.
  • Identify and assess significant EH&S risks, develop risk-reduction measures, prevent health and safety incidents, and minimize environmental impacts.
  • Advise and enable managers and teams to strengthen safety awareness and embed safety and health as a shared leadership responsibility.
  • Promote a sustainable EH&S culture focused on health, prevention, wellbeing, and continuous improvement of the safety culture.
  • Promote cross-functional collaboration and communication and report EH&S risks, strategies, and performance transparently to management.
  • Ensure EH&S compliance and regulatory requirements, including statutory and regulatory reports and permits, and support engagement with authorities and other stakeholders.
  • Provide technical EH&S advice and reviews for facilities, processes, work procedures, work equipment, and new projects, including regular workplace, working-condition, and ergonomics assessments.
  • Support sites and managers in integrating health, safety, and sustainability into daily work and in standardizing and continuously improving the EH&S system.
  • Support change and improvement initiatives, including new facilities, test projects, process optimization, and Kaizen activities, with site assessment and implementation of required measures.
  • Own special EH&S topics and events, including crisis and emergency management, occupational accidents and diseases, environmental matters, and wellbeing topics.
  • Own the development and implementation of holistic health and wellbeing management across the European CSL Plasma network, considering global requirements and local laws.
  • Develop, manage, and evaluate health programs covering prevention, ergonomics, mental health, resilience, and wellbeing; analyze health metrics and derive improvement measures.
  • Promote a sustainable health culture through awareness, communication, and consultation with managers and employees to strengthen health, wellbeing, performance, and attendance.
  • Coordinate with internal and external stakeholders, including company physicians, health service providers, health insurers, authorities, and the wellbeing champion network.
  • Support global health and wellbeing initiatives and ensure local implementation and integration into existing EH&S processes.
  • Support recruitment, retention, training, and development of employees and foster an environment where teams and individuals can develop their potential.
  • Promote employee engagement and accountability through efficient execution, continuous improvement, and active participation in health, safety, and sustainability matters.
  • Strengthen an open and inclusive safety and health culture in which risks are raised transparently and improvement opportunities are jointly identified and implemented.
  • Ensure compliance with environmental, health, and safety regulations at European CSL Plasma sites and monitor implementation by local responsible persons.
  • Manage and further develop reliable EH&S processes and systems for continuous improvement of EH&S performance and employee and donor experience.
  • Own environmental permits and regulatory reporting, including monitoring deadlines, renewals, and site-specific requirements.
  • Coordinate with local EH&S responsible persons to ensure ongoing compliance with current environmental and safety regulations.
  • Manage and monitor EH&S projects within investment and capital projects.
Desired Qualifications
  • Experience developing and implementing health and prevention programs in a regulated environment.

CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Parkville, Australia

Founded

1916

Get referred to CSL

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FY26 HEMGENIX sales rose 25%, validating CSL’s gene-therapy commercialization engine.
  • CSL completed $176 million in FY26 cost savings, ahead of plan.
  • VarmX’s September 2025 option deal adds a potential $2.1 billion anticoagulation franchise.

What critics are saying

  • FY26 revenue fell 1% and underlying NPATA fell 2% on plasma weakness.
  • China albumin sales dropped 17% in FY26 after government cost-containment measures.
  • Pentagon ended the U.S. flu vaccine mandate in 2026, pressuring Seqirus demand and execution.

What makes CSL unique

  • CSL spans plasma, gene therapy, and influenza vaccines, unlike single-platform biotech peers.
  • HEMGENIX remains the only approved hemophilia B gene therapy across the U.S. and Europe.
  • CSL’s global plasma collection and manufacturing network supports hard-to-replicate immunoglobulin and albumin supply.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
Yahoo Finance
Aug 17th, 2026
CSL reports 2% drop in annual profit to $3.14B on weak plasma sales

Australian biopharmaceutical company CSL reported a 2% decline in annual profit on Tuesday, as its core plasma division experienced falling revenue. The company posted an underlying net profit after tax of $3.14 billion on a constant currency basis for the year ended 30 June, down from $3.22 billion the previous year. CSL is among the world's leading flu vaccine manufacturers. The results reflect challenges in the plasma business, which forms a significant part of the company's operations.

Yahoo Finance
May 2nd, 2026
CSL to split Seqirus vaccine unit as shares slide 50% amid restructure and cost cuts

CSL has announced a restructuring plan including the separation of its Seqirus influenza vaccine business into a standalone entity, alongside workforce reductions and plasma collection centre closures. Management cited prolonged margin pressures and operational challenges as drivers for the changes. The announcement follows a sharp share price decline, with CSL trading at A$124.84, down 27.4% year-to-date and 50.1% over the past year. Three-year and five-year returns show declines of 56.3% and 51.0% respectively. The restructuring aims to simplify operations and refocus capital on higher-returning areas. Separating Seqirus could provide clearer visibility into CSL's core plasma and specialty therapies businesses, whilst allowing independent capital allocation decisions. However, investors face execution risks typical of separations of this scale, including one-off charges and operational disruption.

Yahoo Finance
Apr 23rd, 2026
CSL shares hit 2017 low as Pentagon scraps flu vaccine mandate for military personnel

Australian biotech CSL extended losses on Thursday, falling to its lowest level since August 2017, after the US Pentagon scrapped its flu vaccine mandate for military personnel. The stock dropped as much as 0.8%, bringing yearly losses to over 25%. The policy reversal threatens demand from a key institutional buyer, compounding CSL's existing challenges. The company's Seqirus vaccines unit generated $2.17 billion in revenue in fiscal 2025, representing 14% of total revenue. CSL has faced sustained pressure from slowing demand for plasma-derived therapies, higher costs and multiple earnings downgrades. The stock plunged 39% last year, its biggest annual drop since 2002. Analysts cite concerns over falling US flu vaccination rates, weaker Seqirus earnings and delayed strategic plans.

USA Herald
Sep 16th, 2025
CSL to Acquire VarmX in $2.2B Biotech Breakthrough Deal - USA Herald

In a high-stakes move that could reshape emergency medicine, global biotech giant CSL has struck an exclusive option agreement to acquire VarmX, a Netherlands-based biotech, in a deal valued at up to $2.2 billion. The announcement, made Tuesday by EQT Life Sciences, which counts VarmX in its portfolio, underscores just how valuable the Dutch company’s CSL to acquire VarmX in a $2.2B deal, backing breakthrough bleeding drug VMX-C001 with full trial funding.

CSL
Sep 16th, 2025
CSL Limited Celebrates 25 Years on the ASX

Global biotechnology leader, CSL, celebrated the Company’s 25th Anniversary of listing on the Australian Securities Exchange (ASX), commemorating the occasion with a ceremonial bell ring at...